Omeros Corporation (OMER)

Omeros is transitioning into a commercial-stage biotech with YARTEMLEA generating $38.4M of net product sales in the first half of 2026 at ~96% product gross margin and bringing operating results close to break-even in Q2. Liquidity looks adequate near term (about $132M in cash and short-term investments; current ratio ~2) and recent SEC filings do not indicate a going-concern issue. Offsetting this, the company still carries large royalty/convertible-related obligations with meaningful interest expense, negative shareholders’ equity, and headline GAAP earnings remain distorted by one-time and fair-value items—so the investment case hinges on continued sales ramp and reimbursement execution.

A fresh, market-rewarded earnings beat (announced, 2026-09-21; +5% after hours on a Novo Nordisk zaltenibart windfall and Yartemlea launch optimism) is the dominant near-term catalyst; the numeric sentiment delta is indeterminate on a sparse baseline (one unique on-topic scored item) with an item-level improving read at moderate confidence; Red-Flag Screen clean — plaintiff-firm investigations are low-confidence overhang only. Mixed but constructive, forming setup.

Mixed technical picture: the long-term trend is firmly up (price 21% above the SMA50 and 41% above the SMA200, ADX14 45.8, MACD line positive at 1.08), and the short-term frame is stretched to the downside (Williams %R -98.2 at the bottom of its 14-day range) after a four-session pullback to support. Against this, price sits below the SMA20/EMA9/EMA21 stack, the MACD histogram is negative and declining (-0.39), and RSI14 has cooled to a neutral 51.7. Score 3: some bullish, some neutral - a pullback-to-support setup, not a confirmed reversal.